Publications by authors named "Christopher Mill"

Claim this Profile
B
BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML.
Christine E Birdwell, Warren Fiskus, Christopher P Mill, Tapan M Kadia, Naval Daver

Leukemia· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase.
Warren Fiskus, Lucia Masarova, Christopher P Mill, Christine E Birdwell, Kaberi Das

Blood Adv· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1.
Courtney D DiNardo, Wei-Ying Jen, Guillermo Montalban-Bravo, Xuemei Wang, Sanam Loghavi, Christopher P Mill

Blood Neoplasia· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1.
Warren Fiskus, Christopher P Mill, Christine Birdwell, John A Davis, Kaberi Das

Blood Cancer J· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations.
Warren Fiskus, Christopher P Mill, Jessica Piel, Mike Collins, Murphy Hentemann

Blood Cancer J· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML.
Warren Fiskus, Christopher P Mill, Prithviraj Bose, Lucia Masarova, Naveen Pemmaraju

Blood· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor.
Warren Fiskus, Jessica Piel, Mike Collins, Murphy Hentemann, Branko Cuglievan, Christopher P Mill

Blood· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression.
Christine E Birdwell, Warren Fiskus, Tapan M Kadia, Christopher P Mill, Koji Sasaki

Leukemia· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM).
Christopher P Mill, Warren C Fiskus, Courtney D DiNardo, Patrick Reville, John A Davis

Blood Cancer J· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1.
Christopher P Mill, Warren Fiskus, Kaberi Das, John A Davis, Christine E Birdwell

Leukemia· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COVID-19 hospitalisations in immunocompromised individuals in the Omicron era: a population-based observational study using surveillance data in British Columbia, Canada.
Taraneh Bahremand, Jiayun Angela Yao, Christopher Mill, Jolanta Piszczek, Jennifer M Grant

Lancet Reg Health Am· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1.
Warren Fiskus, Christopher P Mill, Christine Birdwell, John A Davis, Kaberi Das

Blood Cancer J· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1.
Warren Fiskus, Naval Daver, Steffen Boettcher, Christopher P Mill, Koji Sasaki

Leukemia· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prescription-related risk factors for opioid-related overdoses in the era of fentanyl contamination of illicit drug supply: A retrospective case-control study.
Kate Smolina, Alexis Crabtree, Mei Chong, Mina Park, Christopher Mill

Subst Abus· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2.
Christopher P Mill, Warren Fiskus, Courtney D DiNardo, Christine Birdwell, John A Davis

Blood· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.
Lauren M Lucas, Vipasha Dwivedi, Jared I Senfeld, Richard L Cullum, Christopher P Mill, S Tyler Miller

Pharmacol Rev· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c).
Warren Fiskus, Steffen Boettcher, Naval Daver, Christopher P Mill, Koji Sasaki

Blood Cancer J· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells.
Warren Fiskus, Taghi Manshouri, Christine Birdwell, Christopher P Mill, Lucia Masarova

Blood Cancer J· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma.
Warren Fiskus, Christopher P Mill, Dimuthu Perera, Christine Birdwell, Qing Deng

Leukemia· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells.
Warren Fiskus, Christopher P Mill, Behnam Nabet, Dimuthu Perera, Christine Birdwell

Blood Cancer J· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EVI1 dysregulation: impact on biology and therapy of myeloid malignancies.
Christine Birdwell, Warren Fiskus, Tapan M Kadia, Courtney D DiNardo, Christopher P Mill

Blood Cancer J· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and application of high-throughput screens for the discovery of compounds that disrupt ErbB4 signaling: Candidate cancer therapeutics.
Richard L Cullum, Lauren M Lucas, Jared I Senfeld, John T Piazza, Logan T Neel, Christopher P Mill

PLoS One· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Poor Correlation of Oral Swabs with Esophageal Eosinophil Counts.
Vishal Avinashi, Justin M Chan, Jonathan W Bush, Bruce A Vallance, Hyungjun Yang, Christopher Mill

Dysphagia· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanistic basis and efficacy of targeting the β-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors.
Dyana T Saenz, Warren Fiskus, Christopher P Mill, Dimuthu Perera, Taghi Manshouri

Blood· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Known fentanyl use among clients of harm reduction sites in British Columbia, Canada.
Mohammad Karamouzian, Kristi Papamihali, Brittany Graham, Alexis Crabtree, Christopher Mill

Int J Drug Policy· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis